Acrivon Therapeutics, Inc.

ACRV

Acrivon Therapeutics, Inc.

ACRV

Insider Sentiment (TTM):

Last Purchase:2026-01-14Last Sale:2025-05-01Shares Purchased (TTM):67,832Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:15,193,810Shares Outstanding:38,724,803Institutional Ownership Pct.:39.24%

Earnings Market Reaction:

Filing Date:2026-05-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Acrivon Therapeutics, Inc. (ACRV) — SEC Financial Statements & Analysis

Acrivon Therapeutics, Inc. (ACRV) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	34	41	35	42	39	40	43	46	25	36	30	38
Short Term Investments	64	77	94	96	110	140	144	135	85	91	112	113
Prepaid Expense And Other Assets Current	1	2	1	1	2	2	2	2	2	2	2	2
Assets Current	99	120	130	138	151	182	189	182	112	130	144	153
Property Plant And Equipment Net	5	5	5	5	5	4	5	3	3	3	2	2
Operating Lease Right Of Use Asset	2	3	3	3	3	4	4	4	4	4	4	4
Long Term Investments	-	-	5	10	15	5	15	40	-	-	-	-
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	2	2	2	2	2	2	1	-	-	0	-	-
Assets	108	130	145	159	176	197	215	231	121	138	151	160
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	2	1	1	4	1	2	1	2	5	2	1
Accrued Liabilities And Other Liabilities	9	12	13	11	9	15	12	9	6	7	7	5
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Liabilities Current	11	16	15	13	14	17	15	11	9	13	9	7
Operating Lease Liability Noncurrent	1	2	2	2	2	3	3	3	4	4	4	4
Liabilities	12	17	17	16	16	20	18	15	13	17	13	11
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	389	387	384	381	377	373	370	368	241	238	236	232
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	0	1	-0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-294	-275	-256	-238	-217	-197	-174	-152	-133	-116	-97	-83
Stockholders Equity	96	113	129	143	160	177	197	216	108	121	138	149
Liabilities And Stockholders Equity	108	130	145	159	176	197	215	231	121	138	151	160
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0	0.001	0.001	0.001	0	0.001	0.001	0.001	0	0.001	0.001
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	39	32	32	31	31	31	31	31	23	23	22	22
Shares Outstanding	39	32	32	31	31	31	31	31	23	23	22	22

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-25.52%	-10.42%	-	-	-	-	-	-	-	-	-	-
2025	18.42%	13.16%	10.53%	1.53%	45.80%	51.91%	14.49%	18.84%	-13.53%	-8.24%	16.47%	-15.88%
2024	-13.28%	-15.43%	-9.69%	11.45%	-3.31%	10.48%	-19.04%	-16.52%	-23.46%	-28.17%	-54.37%	-52.38%
2023	-	-	-	-5.49%	-22.84%	-59.48%	-3.92%	7.19%	-16.78%	31.33%	24.34%	1.40%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	8.98	7.69	8.75	10.31	11.17	10.55	12.75	16.16	12.40	9.75	15.54	21.84
Quick Ratio	8.84	7.57	8.68	10.23	11.04	10.43	12.65	16.00	12.16	9.58	15.28	21.51
Working Capital	88.17M	104.78M	115.47M	124.98M	137.78M	164.42M	174.17M	171.07M	103.10M	116.39M	135.19M	146.27M
Leverage & Debt
Debt to Equity	0.13	0.15	0.13	0.11	0.10	0.11	0.09	0.07	0.12	0.14	0.09	0.07
Interest Coverage TTM	-15.05	-12.98	-11.71	-10.74	-9.56	-9.69	-10.00	-10.04	-10.54	-9.54	-12.93	-17.49
Debt Ratio	0.11	0.13	0.11	0.10	0.09	0.10	0.08	0.06	0.10	0.12	0.09	0.07
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-2.00	-2.02	-2.12	-2.23	-2.18	-2.38	-2.02	-1.91	-2.84	-2.74	-2.86	-2.63
Free Cash Flow Per Share TTM	-1.71	-1.70	-1.77	-1.90	-1.83	-2.03	-1.67	-1.53	-2.23	-1.99	-1.81	-2.41
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-7.74%	-3.29%	6.20%	24.57%	30.62%	33.40%	21.98%	19.30%	-	-	-	-
EPS Growth (1Y)	-8.63%	-15.14%	4.95%	17.03%	-23.06%	-12.84%	-29.31%	-27.46%	-	-	-	-
Valuation Metrics
P/E TTM	-0.70	-1.19	-0.85	-0.53	-0.93	-2.53	-3.47	-3.04	-2.52	-1.80	-3.35	-4.92
P/B	0.56	0.82	0.54	0.32	0.49	1.15	1.35	0.97	1.50	0.90	1.53	1.91
Market Cap	53.83M	92.81M	69.79M	45.77M	77.85M	203.43M	266.74M	209.57M	161.52M	108.62M	211.10M	284.74M
Enterprise Value	19.76M	51.11M	34.39M	3.87M	38.70M	163.61M	223.32M	163.14M	136.50M	72.61M	181.24M	246.26M
Calculated Values
Free Cash Flow TTM	-66.29M	-65.33M	-68.07M	-73.20M	-70.13M	-68.44M	-63.77M	-55.26M	-50.45M	-43.93M	-40.02M	-52.89M
Net Debt	-34.06M	-41.70M	-35.41M	-41.90M	-39.15M	-39.82M	-43.42M	-46.43M	-25.02M	-36.02M	-29.86M	-38.48M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-01-14Purchase

Owner: Blume-Jensen, Peter, Mass…

Title: EVP - Business Operations

Shares: 49,000

Price/Share: $1.68

Value: $82,320.00

Shares Owned: 2,095,771

Relationship: Director,Officer

Ownership: Direct

2026-01-14Purchase

Owner: Levy, Adam D.

Title: Chief Financial Officer

Shares: 8,832

Price/Share: $1.70

Value: $15,014.40

Shares Owned: 20,983

Relationship: Officer

Ownership: Direct

2026-01-13Purchase

Owner: Devroe, Eric

Title: Chief Operating Officer

Shares: 10,000

Price/Share: $1.72

Value: $17,200.00

Shares Owned: 75,308

Relationship: Officer

Ownership: Direct

2025-05-01Sale

Owner: Perceptive, Advisors Llc,…

Title: -

Shares: 298,886

Price/Share: $1.34

Value: $400,507.24

Shares Owned: 3,104,139

Relationship: TenPercentOwner

Ownership: Indirect

2025-04-29Sale

Owner: Perceptive, Advisors Llc,…

Title: -

Shares: 250,000

Price/Share: $1.41

Value: $352,500.00

Shares Owned: 3,840,906

Relationship: TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-01-14	Blume-Jensen, Peter, Mass…	Director,Officer	EVP - Business Operations	Direct	Purchase	49,000	1.68	$82,320.00	2,095,771	4
2026-01-14	Levy, Adam D.	Officer	Chief Financial Officer	Direct	Purchase	8,832	1.70	$15,014.40	20,983	4
2026-01-13	Devroe, Eric	Officer	Chief Operating Officer	Direct	Purchase	10,000	1.72	$17,200.00	75,308	4
2025-05-01	Perceptive, Advisors Llc,…	TenPercentOwner	-	Indirect	Sale	298,886	1.34	$400,507.24	3,104,139	4
2025-04-29	Perceptive, Advisors Llc,…	TenPercentOwner	-	Indirect	Sale	250,000	1.41	$352,500.00	3,840,906	4
2024-04-11	Perceptive, Life Sciences…	TenPercentOwner	-	Indirect	Purchase	2,353,000	8.50	$20,000,500.00	5,360,858	4
2023-06-26	Smolokowski, Wiaczeslaw, …	TenPercentOwner	-	Direct	Sale	16	12.93	$206.88	3,848,632	4
2023-06-15	Nikolaou, Anastasis, Chio…	TenPercentOwner	-	Direct	Sale	2,056	12.14	$24,959.84	3,848,648	4
2023-06-14	Chione, Ltd, Czernik Marc…	TenPercentOwner	-	Direct	Sale	893	12.13	$10,832.09	3,850,704	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

39.24%

Inst. Shares: 15,193,810

Shares Outstanding: 38,724,803

2025-12-31

46.82%

Inst. Shares: 18,030,108

Shares Outstanding: 38,509,281

2025-09-30

44.98%

Inst. Shares: 17,344,499

Shares Outstanding: 38,560,464

2025-06-30

45.81%

Inst. Shares: 17,619,940

Shares Outstanding: 38,461,619

2025-03-31

58.62%

Inst. Shares: 22,481,989

Shares Outstanding: 38,350,444

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	15,193,810	38,724,803	39.24%
2025-12-31	18,030,108	38,509,281	46.82%
2025-09-30	17,344,499	38,560,464	44.98%
2025-06-30	17,619,940	38,461,619	45.81%
2025-03-31	22,481,989	38,350,444	58.62%
2024-12-31	23,197,951	33,791,817	68.65%
2024-09-30	22,924,792	38,105,131	60.16%
2024-06-30	23,427,172	36,132,616	64.84%
2024-03-31	15,117,146	22,590,804	66.92%
2023-12-31	15,267,117	22,078,190	69.15%
2023-09-30	15,075,338	22,081,162	68.27%
2023-06-30	15,108,430	21,971,032	68.77%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Acrivon Therapeutics, Inc. (ACRV) — SEC Financial Statements & Analysis

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.